Hard to Treat Diseases Inc.
Not enough financial coverage to compute a composite score for HTDS. This is typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available data still render below.
Companywww.mellowhope.com
Hard to Treat Diseases Inc. manufactures, supplies, and exports biopharmaceuticals and vaccines in China and internationally. The company offers biologicals, including reteplase (rPA), mycobacterium vaccae, acutobin urinary kallidinogenase, ulinastatin, and cerebroprotein hydrolysate for injection; chemicals, such as cobratide injection, entecavir capsule, HES, dasatinib tablets, thymosin a1 for injection, imipenem and cilastatin sodium for injection, and meropenem for injection; and vaccines, which include rabies vaccine, ACYW135 meningococcal vaccine, influenza vaccine, Hepatitis A, and varicella vaccine.
- CEO
- Shimin Yuan
- IPO
- 1998
- HQ
- Shenzhen, CN
Price Chart
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.70
- Avg Volume
- 244.28K
Get TickerSpark's AI analysis on HTDS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our HTDS Coverage
We haven't published any research on HTDS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HTDS Report →